Table 2.
Wave | Predose baseline score | Postdose score | ||
---|---|---|---|---|
1 month | 2 months | |||
N100 latency | Placebo | 116.80 ± 1.385 | 114.50 ± 11.97 | 113.85 ± 10.24 |
400 mg | 114.35 ± 11.44 | 113.25 ± 11.85 | 110.35 ± 10.17 | |
800 mg | 114.05 ± 8.31 | 109.95 ± 8.72 | 106.75 ± 9.13 | |
| ||||
N100 amplitude | Placebo | 5.70 ± 10.08 | 5.65 ± 1.08 | 5.70 ± 1.07 |
400 mg | 5.90 ± 1.37 | 6.40 ± 1.18 | 6.55 ± 1.05 | |
800 mg | 5.75 ± 1.29 | 7.05 ± 1.19** | 6.90 ± 0.96*** | |
| ||||
P300 latency | Placebo | 332.70 ± 12.96 | 330.30 ± 11.02 | 332.35 ± 8.99 |
400 mg | 332.25 ± 13.81 | 329.45 ± 11.78 | 323.85 ± 13.10 | |
800 mg | 332.90 + 10.20 | 325.60 ± 12.91 | 321.35 ± 9.77*** | |
| ||||
P300 amplitude | Placebo | 7.25 ± 1.10 | 7.25 ± 1.06 | 7.20 ± 1.05 |
400 mg | 7.25 ± 1.01 | 7.50 ± 1.23 | 8.10 ± 1.16** | |
800 mg | 7.20 ± 1.10 | 7.90 ± 1.02 | 8.40 ± 1.35** |
The amplitudes and latencies of event-related potential elicited by oddball paradigm at Cz electrode were measured. Data are presented as mean ±SD (n = 20/group).
**, ***P value < 0.05, 0.01, and 0.001 compared to placebo-treated group, respectively.